Former SEC Officials on Life Sciences Companies: SEC Enforcement Priorities and Recent Developments

Partners and former Security and Exchange Commission (SEC) officials, Dan Hawke, Jane Norberg, and Christian Schultz discussed SEC enforcement priorities, developing policies, recent litigation trends, and other key updates concerning publicly traded pharmaceutical, biotechnology, medical device, and healthcare product and services companies. This one-hour webinar provided in-house counsel and executives of life sciences companies with the latest on various hot topics, including:

• Disclosure issues during the life cycle of a product
• Risks related to improper revenue recognition and “channel stuffing”
• Accounting, restatements, and disclosure controls
• Artificial Intelligence
• New cybersecurity disclosure requirements
• Environmental, Social, and Governance issues
• Insider trading
• Whistleblower issues, including a spotlight on the new Department of Justice whistleblower program

Please click here to view the webinar.